secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2026-08-11T10:59:00+00:00
Accession:  0001628280-26-055484
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q2 net loss widens to $15.2M; cash $208M; SL-325 Phase 1 positive
-------------------------------------------------------------------------------

- Q2 2026 net loss $15.2M ($0.12/sh) vs $12.5M ($0.24/sh) in Q2 2025; R&D $11.7M, G&A $4.5M.
- Cash, equivalents and short-term investments $208.3M at 6/30/26, expected to fund operations into 2029.
- SL-325 Phase 1: 3.7% ADA, >3-month DR3 blockade at ≥1mg/kg, favorable safety, no DR3 agonism.
- RECEPTIVE-CD1 Phase 2b Crohn's starts Q3 2026: ~232 pts, primary endpoint endoscopic response at 12 wks, data 1H 2028.
- SL-846 bispecific (DR3 x IL-23R) in IND-enabling tox; Phase 1 healthy volunteer trial expected 2027; poster at UEGW Oct 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/0001628280-26-055484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/sttk-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-055484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer